Health insurers are under growing pressure to modernise their technology stacks while safeguarding the privacy of millions of policyholders.
With customer expectations rising and compliance frameworks tightening, QA and testing teams are searching for ways to accelerate delivery without risking exposure of sensitive health data.
Increasingly, they are finding the answer in synthetic data, engineered, rule-based datasets that mimic real patient and claims information without containing any identifiable details.
A growing number of insurers are now turning to synthetic data to transform how they test and validate critical claims systems. The approach reduces cost, protects privacy and enables full-scale, production-level testing without the legal and operational risks associated with using real customer information.
This is a timely topic that will feature prominently at next month’s QA Healthcare & Insurance Forum London, where K2View plans to talk about cloning and masking PHI data for secure and compliant app testing with GenAI.
In one recent case study, which was shared with QA Financial, a major U.S. health insurer used synthetic, HIPAA-compliant X12 EDI data to overhaul its claims-processing platform.
HIPAA stands for the Health Insurance Portability and Accountability Act, a U.S. federal law that sets strict standards for protecting patients’ medical information, while X12 EDI refers to the Electronic Data Interchange (EDI) standards developed by the Accredited Standards Committee X12, which define how healthcare data is exchanged electronically between insurers, providers, and clearing houses.
The initiative was part of a wider digital transformation aimed at accelerating release cycles and improving integration testing across hundreds of dependent systems.
By generating realistic but fully anonymised datasets conforming to standards such as 837, 835 and 834, the QA team could perform end-to-end tests at production-level volumes, all without exposing protected health information.
837 transmits healthcare claims from providers to insurers, the 835 involves reports claim payments and remittance details back to providers, and the 834 rule deals with enrollment and updates to members’ health plan benefits.
Data replacement
The impact on testing velocity was immediate. Test cycles that once depended on masked legacy data, often inconsistent and incomplete, were replaced with on-demand, rule-driven data generation that mirrored every conceivable claim scenario.
Synthetic datasets allowed engineers to recreate complex billing hierarchies, benefit exceptions and multi-provider chains, achieving far greater coverage in regression and performance testing.
From a compliance perspective, the shift was equally transformative. The insurer’s QA and data-governance teams adopted a “synthetic-first” policy for all pre-production environments, ensuring that no personally identifiable information could leak into development or staging.
This new approach also enabled negative testing, where malformed or contradictory claims records were deliberately generated to validate error-handling logic and system resilience.
The model mirrors what many financial institutions are now practising under resilience frameworks such as DORA in Europe and CPS 230 in Australia, simulating realistic, risk-based scenarios at scale to test operational continuity.
For insurers, the ability to continuously validate claims systems, detect performance bottlenecks early and maintain full audit trails of testing activity offers clear regulatory and business benefits.
Synthetic data is no longer just a workaround for privacy restrictions; it has become a cornerstone of digital QA strategy in healthcare and insurance.
As claims processing moves deeper into cloud-native and AI-driven architectures, the ability to generate, control and reuse synthetic datasets will determine how effectively insurers balance speed, security and compliance. In an industry where every record is sensitive and every delay costly, synthetic data is proving that safer testing can also mean faster innovation.
RELEVANT SESSION: At tomorrow’s QA Healthcare & Insurance Forum London 2025, K2View plans to discuss cloning and masking PHI data for secure and compliant app testing with GenAI.
Wednesday November 26 at 9.30. More information can be found here.
TOMORROW
Why not become a QA Financial subscriber?
It’s entirely FREE
* Receive our weekly newsletter every Wednesday * Get priority invitations to our Forum events *
REGULATION & COMPLIANCE
Looking for more news on regulations and compliance requirements driving developments in software quality engineering at financial firms? Visit our dedicated Regulation & Compliance page here.
READ MORE
- Inside JPMorgan’s $18bn QA push with OmniAI reshaping testing
- As AI takes hold, insurance firms face a new testing mandate
- K2view’s Amitai Richman calls out the ‘real bottleneck’ in healthcare and insurance
- AI in QA: how flexible testing is redefining assurance for financial firms
- Explainer: Why site reliability engineering is gaining momentum in banking
WATCH NOW
